BioXcel Therapeutics, Inc. Financials

Market Capitalization $16.9 Million as of Jan. 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-0.42
Forward PE	-1.40
Price to Sales TTM	$56.94
Price to Book MRQ	$
Enterprise to Revenue	83.15
Enterprise to EBITDA	-0.69

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	8.70%
Operating Margin	-5285.90%
Return on Assets TTM	-74.95%
Return on Equity TTM	-1766.94%

Income Statement

Revenue TTM	$1,380,000
Revenue per Share TTM	$0.05
Quarterly Revenue Growth	58.00%
Gross Profit TTM	$120,000
EBITDA	$-167,300,992
Net Income to Common TTM	$-179,052,992
Diluted EPS TTM	$-6.15
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$65,221,000
Total Cash per Share MRQ	$2.13
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.79
Current Ratio MRQ	2.65
Book Value per Share MRQ	$-1.89

Cash Flow

Operating Cash Flow TTM	$-155,006,000
Levered Free Cash Flow TTM	$-96,554,128

BTAI Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	30,576,700
Float Shares	20,186,412
Avg 10 Volume	365,337
Avg 30 Volume	None
Shares Short	2,087,650
Short Ratio	4.08
Short % of Shares	23.64%
% Held by Insiders	24.39%
% Held by Institutions	25.87%

Stock Price Summary

Beta	0.39
Fifty Two Week Low	$1.91
Fifty Two Week High	$29.56
Fifty Two Week Change	-924.51%
Day 50 MA	$2.82
Day 200 MA	$3.74

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date